國立虎尾科技大學 |

Post-authorization safety studies of medicinal products = the PASS book /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Post-authorization safety studies of medicinal products/ edited by Ayad K. Ali, Abraham G. Hartzema.
其他題名:	the PASS book /
其他作者:	Ali, Ayad K.,
出版者:	London, United Kingdom :Academic Press, an imprint of Elsevier, : 2018.,
面頁冊數:	1 online resource.
附註:	Includes index.
標題:	Drugs - Testing. -
電子資源:	https://www.sciencedirect.com/science/book/9780128092170
ISBN:	9780128092088 (electronic bk.)

Post-authorization safety studies of medicinal products = the PASS book /
Post-authorization safety studies of medicinal productsthe PASS book /[electronic resource] :edited by Ayad K. Ali, Abraham G. Hartzema. - London, United Kingdom :Academic Press, an imprint of Elsevier,2018. - 1 online resource.

Includes index.

Includes bibliographical references and index.

Intro; Title page; Table of Contents; Copyright; List of Contributors; Foreword; Chapter 1. Introduction; Risk Management and Benefit-Risk Evaluation; Transparency; About This Book; Chapter 2. Risk Management Process; Chapter 2.1. Risk Assessment; Chapter 2.2. Risk Minimization; Chapter 3. Data Sources for Post-Authorization Safety Studies; Chapter 3.1. Health Insurance Administrative Claims; Chapter 3.2. Electronic Medical Records; Chapter 3.3. Registries; Chapter 3.4. Big Data; Chapter 3.5. Social Media; Chapter 4. Study Designs for Post-Authorization Safety Studies

Post-Authorization Safety Studies of Medicinal Products: The PASS Book bridges the gap in the literature by providing a complete look at post-authorization safety studies and important pharmacoepidemiology and pharmacovigilance aspects. It covers various types and limitations of active surveillance programs, including the use of large databases and disparate data sources for rapid signal detection, as well as novel and advanced design and analysis approaches for causal interference from observational data. This book serves as an important reference for pharmacovigilance scientists and pharmacoepidemiologists who are searching for the appropriate study design to answer safety research questions. Readers will be able to effectively and efficiently design and interpret findings from post-authorization safety studies with the goal of improving the benefit-risk balance of a drug in order to optimize patient safety.

ISBN: 9780128092088 (electronic bk.)Subjects--Topical Terms:

581825
Drugs
--Testing.Index Terms--Genre/Form:

554714
Electronic books.

LC Class. No.: RM301.9

Dewey Class. No.: 615.7/040287

National Library of Medicine Call No.: 2018 H-178

Post-authorization safety studies of medicinal products = the PASS book /
LDR:03668cam a2200325 a 4500 001 1043224
006 m o d
007 cr cnu---unuuu
008 211216s2018 enka gob 001 0 eng d
020 $a 9780128092088 (electronic bk.)
020 $a 0128092084 (electronic bk.)
020 $a 9780128092170
020 $a 0128092173
035 $a (OCoLC)1040694326
035 $a on1040694326
040 $a N$T $b eng $c N$T $d OPELS $d N$T $d EBLCP $d YDX $d OCLCF $d NLE $d MERUC $d UKMGB $d U3W $d LVT $d D6H $d CASUM $d OCLCQ $d OCLCA $d OCLCQ $d OCLCA $d S2H $d OCLCO $d UX1 $d VT2
041 0 $a eng
050 4 $a RM301.9
060 0 0 $a 2018 H-178
060 1 0 $a QV 771
082 0 4 $a 615.7/040287 $2 23
245 0 0 $a Post-authorization safety studies of medicinal products $h [electronic resource] : $b the PASS book / $c edited by Ayad K. Ali, Abraham G. Hartzema.
260 $a London, United Kingdom : $b Academic Press, an imprint of Elsevier, $c 2018.
300 $a 1 online resource.
500 $a Includes index.
504 $a Includes bibliographical references and index.
505 0 $a Intro; Title page; Table of Contents; Copyright; List of Contributors; Foreword; Chapter 1. Introduction; Risk Management and Benefit-Risk Evaluation; Transparency; About This Book; Chapter 2. Risk Management Process; Chapter 2.1. Risk Assessment; Chapter 2.2. Risk Minimization; Chapter 3. Data Sources for Post-Authorization Safety Studies; Chapter 3.1. Health Insurance Administrative Claims; Chapter 3.2. Electronic Medical Records; Chapter 3.3. Registries; Chapter 3.4. Big Data; Chapter 3.5. Social Media; Chapter 4. Study Designs for Post-Authorization Safety Studies
505 8 $a Chapter 4.1. Drug Utilization and Prescription-Event Monitoring StudiesChapter 4.2. Self-Controlled Studies; Chapter 4.3. Cohort and Nested Case-Control Studies; Chapter 4.4. Enriched Studies; Chapter 4.5. Prospective Studies; Chapter 5. Analytical Approaches for Post-Authorization Safety Studies; Chapter 5.1. Exposure Propensity Scores; Chapter 5.2. Disease Risk Scores; Chapter 5.3. Instrumental Variables; Chapter 5.4. Data Analytic Platforms; Chapter 5.5. Proactive Safety Surveillance; Chapter 6. Benefit-Risk Evaluation; Chapter 6.1. Benefit-Risk Evaluation Frameworks
505 8 $a Chapter 6.2. Post-Authorization Effectiveness StudiesChapter 7. Post-Authorization Safety Studies for Specialty Products; Chapter 7.1. Post-Authorization Safety Studies for Biosimilars and Interchangeable Biologic Products; Chapter 7.2. Post-Authorization Safety Studies for Medical Devices and Combination Products; Chapter 7.3. Post-Authorization Safety Studies for Vaccines; Chapter 8. The European Union Post-Authorization Study Register; Disclaimer/Acknowledgments; Introduction; Index
520 $a Post-Authorization Safety Studies of Medicinal Products: The PASS Book bridges the gap in the literature by providing a complete look at post-authorization safety studies and important pharmacoepidemiology and pharmacovigilance aspects. It covers various types and limitations of active surveillance programs, including the use of large databases and disparate data sources for rapid signal detection, as well as novel and advanced design and analysis approaches for causal interference from observational data. This book serves as an important reference for pharmacovigilance scientists and pharmacoepidemiologists who are searching for the appropriate study design to answer safety research questions. Readers will be able to effectively and efficiently design and interpret findings from post-authorization safety studies with the goal of improving the benefit-risk balance of a drug in order to optimize patient safety.
650 0 $a Drugs $x Testing. $3 581825
650 0 $a Drug monitoring. $3 903499
650 1 2 $a Drug Evaluation. $3 557396
650 1 2 $a Product Surveillance, Postmarketing. $3 966134
650 2 2 $a Risk Management. $3 569483
650 7 $a MEDICAL $x Pharmacology. $2 bisacsh $3 791669
655 0 $a Electronic books. $2 local $3 554714
700 1 $a Ali, Ayad K., $e editor. $3 1344359
700 1 $a Hartzema, Abraham G., $e editor. $3 1344360
856 4 0 $u https://www.sciencedirect.com/science/book/9780128092170